Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CanSino Biologics Inc.
  6. Summary
    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
09/20/2021 09/21/2021 09/23/2021 09/24/2021 09/27/2021 Date
273.8 278.6 282 280.2 285 Last
455398 577832 721537 593772 504796 Volume
-2.21% +1.75% +1.22% -0.64% +1.71% Change
Estimated financial data (e)
Sales 2021 9 984 M 1 547 M 1 547 M
Net income 2021 5 282 M 818 M 818 M
Net cash position 2021 5 073 M 786 M 786 M
P/E ratio 2021 11,7x
Yield 2021 0,00%
Sales 2022 23 264 M 3 603 M 3 603 M
Net income 2022 9 773 M 1 514 M 1 514 M
Net cash position 2022 17 639 M 2 732 M 2 732 M
P/E ratio 2022 5,78x
Yield 2022 0,00%
Capitalization 71 379 M 11 055 M 11 056 M
EV / Sales 2021 6,64x
EV / Sales 2022 2,31x
Nbr of Employees 726
Free-Float 37,1%
More Financials
Company
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia. 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of CanSino Biologics Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about CANSINO BIOLOGICS INC.
09/24CANSINO BIOLOGICS : CanSinoBIO's COVID vaccine, tested at lower dosage, safe for children ..
RE
09/20CANSINO BIOLOGICS INC.(XSSC : 688185) added to S&P Global BMI Index
CI
09/10Cansino Biologics Inc. Announces Executive Changes
CI
09/07CANSINO BIOLOGICS : Indonesia approves J&J, Cansino COVID-19 vaccines for emergency use
RE
09/07SINOVAC BIOTECH : Mixing CanSinoBIO, Sinovac COVID shots induces stronger response than Si..
RE
09/06CORONAVIRUS PANDEMIC : Chinese developer shares efficacy of inhaled vaccines
PU
08/27CANSINO BIOLOGICS : COVID shot drives CanSinoBIO's first six-month profit since at least 2..
RE
08/27Cansino Biologics Inc. Reports Audited Consolidated Earnings Results for the Six Months..
CI
08/13Certain A Shares of CanSino Biologics Inc. are subject to a Lock-Up Agreement Ending on..
CI
08/13CANSINO BIOLOGICS INC.(SHSE : 688185) added to Shanghai Stock Exchange Composite Index
CI
08/13CANSINO BIOLOGICS INC.(SHSE : 688185) added to Shanghai Stock Exchange A Share Index
CI
08/06CANSINO BIOLOGICS : CanSinoBIO COVID-19 says booster shot can reverse drop in antibodies
RE
07/30Solution Biologics Sdn Bhd Signs Finished Product and a Bulk Product Agreement with Can..
CI
07/29CANSINO BIOLOGICS : Announcement change of venue of the 2021 first extraordinary general m..
PU
07/29CANSINO BIOLOGICS : Inhaled COVID-19 Vaccine Candidate Yields Positive Results in Early Tr..
MT
More news
News in other languages on CANSINO BIOLOGICS INC.
06/01L'OMS approuve le vaccin développé par le chinois Sinovac
05/28México aprueba uso "de emergencia" de vacuna contra COVID-19 de Janssen-Cilag
05/14COVID : ricercatore tedesco dice di aver scoperto causa trombosi vaccini
05/06Las farmacéuticas caen en Bolsa ante el respaldo de Biden a exención de patentes de COV..
05/06MÄRKTE ASIEN/Tokio sehr fest - Chin. Impfstoffhersteller stürzen ab
More news
Analyst Recommendations on CANSINO BIOLOGICS INC.
More recommendations
Chart CANSINO BIOLOGICS INC.
Duration : Period :
CanSino Biologics Inc. Technical Analysis Chart | 6185 | CNE100003F01 | MarketScreener
Technical analysis trends CANSINO BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 236,41 CNY
Average target price 308,77 CNY
Spread / Average Target 30,6%
EPS Revisions
Managers and Directors
Xue Feng Yu Chairman, Chief Executive Officer & GM
Xi Luo Chief Financial Officer
Jiang Feng Li Chairman-Supervisory Board
Tao Zhu Executive Director, CSO & Deputy General Manager
Jun Qiang Li Senior Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CANSINO BIOLOGICS INC.61.47%5 902
CSL LIMITED8.15%103 032
WUXI BIOLOGICS (CAYMAN) INC.18.58%64 160
SAMSUNG BIOLOGICS CO.,LTD.11.38%51 643
BIOGEN INC.19.13%43 475
ALEXION PHARMACEUTICALS, INC.0.00%40 336